{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:56:57Z","timestamp":1787320617001,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00259-025-07617-0","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T01:48:39Z","timestamp":1760492919000},"page":"1869-1880","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Safety and efficacy of 177Lu-FAPI-XT radioligand therapy in patients with advanced sarcoma and other cancer entities: first-in-human, dose-escalation study"],"prefix":"10.1007","volume":"53","author":[{"given":"Honghong","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijuan","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuwei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shasha","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9948-2633","authenticated-orcid":false,"given":"Ruimin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"key":"7617_CR1","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.7150\/thno.69475","volume":"12","author":"L Zhao","year":"2022","unstructured":"Zhao L, Chen J, Pang Y, Fu K, Shang Q, Wu H, et al. Fibroblast activation protein-based theranostics in cancer research: a state-of-the-art review. Theranostics. 2022;12:1557\u201369. https:\/\/doi.org\/10.7150\/thno.69475.","journal-title":"Theranostics"},{"key":"7617_CR2","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00259-024-06795-7","volume":"52","author":"SS Banihashemian","year":"2024","unstructured":"Banihashemian SS, Akbari ME, Pirayesh E, Divband G, Abolhosseini Shahrnoy A, Nami R, et al. Feasibility and therapeutic potential of [(177)Lu]Lu-FAPI-2286 in patients with advanced metastatic sarcoma. Eur J Nucl Med Mol Imaging. 2024;52:237\u201346. https:\/\/doi.org\/10.1007\/s00259-024-06795-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7617_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/genes13010135","volume":"13","author":"PJ Vlachostergios","year":"2022","unstructured":"Vlachostergios PJ, Karathanasis A, Tzortzis V. Expression of fibroblast activation protein is enriched in neuroendocrine prostate cancer and predicts worse survival. Genes. 2022;13:135. https:\/\/doi.org\/10.3390\/genes13010135.","journal-title":"Genes"},{"key":"7617_CR4","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1002\/cam4.4452","volume":"11","author":"KM Brown","year":"2022","unstructured":"Brown KM, Xue A, Smith RC, Samra JS, Gill AJ, Hugh TJ. Cancer-associated stroma reveals prognostic biomarkers and novel insights into the tumour microenvironment of colorectal cancer and colorectal liver metastases. Cancer Med. 2022;11:492\u2013506. https:\/\/doi.org\/10.1002\/cam4.4452.","journal-title":"Cancer Med"},{"key":"7617_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13215501","author":"T MacNeil","year":"2021","unstructured":"MacNeil T, Vathiotis IA, Shafi S, Aung TN, Zugazagoitia J, Gruver AM, et al. Multiplex quantitative analysis of tumor-infiltrating lymphocytes, cancer-associated fibroblasts, and CD200 in pancreatic cancer. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13215501.","journal-title":"Cancers (Basel)"},{"key":"7617_CR6","doi-asserted-by":"publisher","first-page":"e194003","DOI":"10.1148\/rycan.2019194003","volume":"1","author":"DK Hathi","year":"2019","unstructured":"Hathi DK, Jones EF. (68)Ga FAPI PET\/CT: tracer uptake in 28 different kinds of cancer. Radiol Imaging Cancer. 2019;1:e194003. https:\/\/doi.org\/10.1148\/rycan.2019194003.","journal-title":"Radiol Imaging Cancer"},{"key":"7617_CR7","doi-asserted-by":"publisher","first-page":"e957","DOI":"10.1093\/oncolo\/oyac216","volume":"27","author":"R AlSadi","year":"2022","unstructured":"AlSadi R, Bouhali O, Dewji S, Djekidel M. 177Lu-PSMA therapy for metastatic Castration-Resistant prostate cancer: A Mini-Review of State-of-the-Art. Oncologist. 2022;27:e957\u201366. https:\/\/doi.org\/10.1093\/oncolo\/oyac216.","journal-title":"Oncologist"},{"key":"7617_CR8","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/s1470-2045(21)00572-6","volume":"22","author":"JR Strosberg","year":"2021","unstructured":"Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, et al. (177)lu-dotatate plus long-acting octreotide versus high\u2013dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22:1752\u201363. https:\/\/doi.org\/10.1016\/s1470-2045(21)00572-6.","journal-title":"Lancet Oncol"},{"key":"7617_CR9","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s00259-023-06482-z","volume":"51","author":"MP Yadav","year":"2024","unstructured":"Yadav MP, Ballal S, Martin M, Roesch F, Satapathy S, Moon ES, et al. Therapeutic potential of [(177)Lu]Lu-DOTAGA-FAPi dimers in metastatic breast cancer patients with limited treatment options: efficacy and safety assessment. Eur J Nucl Med Mol Imaging. 2024;51:805\u201319. https:\/\/doi.org\/10.1007\/s00259-023-06482-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7617_CR10","doi-asserted-by":"publisher","first-page":"415","DOI":"10.2967\/jnumed.120.259192","volume":"63","author":"RP Baum","year":"2022","unstructured":"Baum RP, Schuchardt C, Singh A, Chantadisai M, Robiller FC, Zhang J, et al. Feasibility, biodistribution, and preliminary dosimetry in peptide-targeted radionuclide therapy of diverse adenocarcinomas using (177)Lu-FAP-2286: first-in-humans results. J Nucl Med. 2022;63:415\u201323. https:\/\/doi.org\/10.2967\/jnumed.120.259192.","journal-title":"J Nucl Med"},{"key":"7617_CR11","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1089\/thy.2021.0412","volume":"32","author":"S Ballal","year":"2022","unstructured":"Ballal S, Yadav MP, Moon ES, Roesch F, Kumari S, Agarwal S, et al. Novel fibroblast activation protein inhibitor-based targeted theranostics for radioiodine-refractory differentiated thyroid cancer patients: a pilot study. Thyroid. 2022;32:65\u201377. https:\/\/doi.org\/10.1089\/thy.2021.0412.","journal-title":"Thyroid"},{"key":"7617_CR12","doi-asserted-by":"publisher","first-page":"4740","DOI":"10.1158\/1078-0432.Ccr-23-1983","volume":"29","author":"H Fu","year":"2023","unstructured":"Fu H, Huang J, Zhao T, Wang H, Chen Y, Xu W, et al. Fibroblast activation protein-targeted radioligand therapy with 177Lu-EB-FAPI for metastatic radioiodine-refractory thyroid cancer: first-in-human, dose-escalation study. Clin Cancer Res. 2023;29:4740\u201350. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-23-1983.","journal-title":"Clin Cancer Res"},{"key":"7617_CR13","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1097\/rlu.0000000000005297","volume":"49","author":"Y Xie","year":"2024","unstructured":"Xie Y, Ma J, Tang W, Zhang Y, Zhang C, Chen Y. Efficacy and safety evaluation of 177Lu-FAP-2286 in the treatment of advanced lung cancer. Clin Nucl Med. 2024;49:830\u20137. https:\/\/doi.org\/10.1097\/rlu.0000000000005297.","journal-title":"Clin Nucl Med"},{"key":"7617_CR14","unstructured":"Shen Z, Wang R. Comparative evaluation of a novel FAP-targeted radioactive [68Ga]Ga-XT117 and [18F]F-FDG in patients with solid tumors: a pilot clinical PET imaging study. SNMMI, Toronto, Canada, 2024."},{"key":"7617_CR15","unstructured":"He X, Zhao R, Wang X, Lv J, Xu S, Liang S et al. Novel FAP-targeted PET tracer [64Cu]Cu-FAPI-XT117 in patients with multiple solid tumor: a pilot study. SNMMI, Toronto, Canada, 2024."},{"key":"7617_CR16","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1007\/s00259-010-1422-4","volume":"37","author":"C Hindorf","year":"2010","unstructured":"Hindorf C, Glatting G, Chiesa C, Lind\u00e9n O, Flux G. EANM dosimetry committee guidelines for bone marrow and whole-body dosimetry. Eur J Nucl Med Mol Imaging. 2010;37:1238\u201350. https:\/\/doi.org\/10.1007\/s00259-010-1422-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7617_CR17","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1007\/s00259-023-06144-0","volume":"50","author":"BM Priv\u00e9","year":"2023","unstructured":"Priv\u00e9 BM, Boussihmad MA, Timmermans B, van Gemert WA, Peters SMB, Derks YHW, et al. Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies. Eur J Nucl Med Mol Imaging. 2023;50:1906\u201318. https:\/\/doi.org\/10.1007\/s00259-023-06144-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7617_CR18","doi-asserted-by":"publisher","first-page":"4346","DOI":"10.1158\/1078-0432.ccr-22-1432","volume":"28","author":"WP Fendler","year":"2022","unstructured":"Fendler WP, Pabst KM. Safety and efficacy of 90Y-FAPI-46 radioligand therapy in patients with advanced sarcoma and other cancer entities. Clin Cancer Res. 2022;28:4346\u201353. https:\/\/doi.org\/10.1158\/1078-0432.ccr-22-1432.","journal-title":"Clin Cancer Res"},{"key":"7617_CR19","doi-asserted-by":"publisher","first-page":"252","DOI":"10.2967\/jnumed.123.266411","volume":"65","author":"R Hamacher","year":"2024","unstructured":"Hamacher R, Pabst KM, Cheung PF, Heilig CE, H\u00fcllein J, Liffers ST, et al. Fibroblast activation protein \u03b1-directed imaging and therapy of solitary fibrous tumor. J Nucl Med. 2024;65:252\u20137. https:\/\/doi.org\/10.2967\/jnumed.123.266411.","journal-title":"J Nucl Med"},{"key":"7617_CR20","doi-asserted-by":"publisher","first-page":"s4","DOI":"10.2967\/jnumed.123.266983","volume":"65","author":"L Zhao","year":"2024","unstructured":"Zhao L, Kang F, Pang Y, Fang J, Sun L, Wu H, et al. Fibroblast activation protein inhibitor tracers and their Preclinical, Translational, and clinical status in China. J Nucl Med. 2024;65:s4\u201311. https:\/\/doi.org\/10.2967\/jnumed.123.266983.","journal-title":"J Nucl Med"},{"key":"7617_CR21","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/s0140-6736(24)01653-2","volume":"404","author":"MJ Morris","year":"2024","unstructured":"Morris MJ, Castellano D, Herrmann K, de Bono JS, Shore ND, Chi KN, et al. (177)Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. Lancet. 2024;404:1227\u201339. https:\/\/doi.org\/10.1016\/s0140-6736(24)01653-2.","journal-title":"Lancet"},{"key":"7617_CR22","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1007\/s00259-024-06703-z","volume":"51","author":"Y Tan","year":"2024","unstructured":"Tan Y, Li J, Zhao T, Zhou M, Liu K, Xiang S, et al. Clinical translation of a novel FAPI dimer [(68)Ga]Ga-LNC1013. Eur J Nucl Med Mol Imaging. 2024;51:2761\u201373. https:\/\/doi.org\/10.1007\/s00259-024-06703-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7617_CR23","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/0360-3016(91)90171-y","volume":"21","author":"B Emami","year":"1991","unstructured":"Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109\u201322. https:\/\/doi.org\/10.1016\/0360-3016(91)90171-y.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"7617_CR24","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, Nilsson S, Heinrich D, Helle SI, O\u2019Sullivan JM, Foss\u00e5 SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213\u201323. https:\/\/doi.org\/10.1056\/NEJMoa1213755.","journal-title":"N Engl J Med"},{"key":"7617_CR25","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091\u2013103. https:\/\/doi.org\/10.1056\/NEJMoa2107322.","journal-title":"N Engl J Med"},{"key":"7617_CR26","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of (177)Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1607427.","journal-title":"N Engl J Med"},{"key":"7617_CR27","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1200\/jco.2002.11.076","volume":"20","author":"TE Witzig","year":"2002","unstructured":"Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2002;20:2453\u201363. https:\/\/doi.org\/10.1200\/jco.2002.11.076.","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07617-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07617-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07617-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T04:43:28Z","timestamp":1769834608000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07617-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["7617"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07617-0","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]},"assertion":[{"value":"29 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The ethical approval was obtained from local institutional review board. The informed consent was obtained from individual participant included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval\u00a0and informed consent"}},{"value":"All of the authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Sinotau Pharmaceutical Group provided\n                      177\n                      Lu-FAPI-XT (including precursors and radionuclides) for the study but had no role in study design, data collection, analysis, interpretation, or manuscript preparation, and did not provide any financial or other research support.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}